Payment overview · 2025
General Payments
$291.74
10 reported records · 5 companies
Healthcare provider profile · identity verified
Kent A Darsey, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MERIDIAN, MS · NPI 1851396337
Verified facts
What the public records show
CMS Open Payments records show Kent A Darsey, M.D. received $291.74 in general payments during 2025 across 10 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 42.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $124.70 | 42.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.21 | 22.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.36 | 15.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.12 | 12.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.35 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $291.74 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $124.70 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $64.21 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $46.36 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $46.36 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $36.12 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.12 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $14.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 80 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
191 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 813 | 324 |
| Pravastatin Sodium | Pravastatin Sodium | 499 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 473 | 112 |
| Clonazepam | Clonazepam | 461 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 443 | 114 |
| Potassium Chloride | Potassium Chloride | 373 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 341 | 99 |
| Metformin Hcl | Metformin Hcl | 339 | 91 |
| Furosemide | Furosemide | 313 | 91 |
| Meloxicam | Meloxicam | 310 | 90 |
| Gabapentin | Gabapentin | 304 | 82 |
| Cephalexin | Cephalexin | 278 | 170 |
| Hydrochlorothiazide | Hydrochlorothiazide | 250 | 73 |
| Omeprazole | Omeprazole | 248 | 67 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 231 | 100 |
| Atorvastatin Calcium | Atorvastatin Calcium | 196 | 59 |
| Ozempic | Semaglutide | 191 | 29 |
| Fenofibrate | Fenofibrate Nanocrystallized | 181 | 51 |
| Allopurinol | Allopurinol | 178 | 48 |
| Tramadol Hcl | Tramadol Hcl | 177 | 40 |
| Lisinopril | Lisinopril | 176 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 42 |
| Montelukast Sodium | Montelukast Sodium | 174 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 165 | 31 |
| Eszopiclone | Eszopiclone | 156 | 31 |
| Glimepiride | Glimepiride | 131 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 130 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 125 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 119 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 36 |
| Simvastatin | Simvastatin | 105 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 102 | 79 |
| Amitriptyline Hcl | Amitriptyline Hcl | 101 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 47 |
| Metoclopramide Hcl | Metoclopramide Hcl | 84 | 29 |
| Sertraline Hcl | Sertraline Hcl | 84 | 16 |
| Eliquis | Apixaban | 80 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 25 |
| Carvedilol | Carvedilol | 77 | 28 |
| Donepezil Hcl | Donepezil Hcl | 73 | 17 |
| Atenolol | Atenolol | 70 | 20 |
| Trazodone Hcl | Trazodone Hcl | 68 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 67 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 12 |
| Azithromycin | Azithromycin | 61 | 54 |
| Losartan Potassium | Losartan Potassium | 61 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 57 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 53 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 14 |
| Meclizine Hcl | Meclizine Hcl | 51 | 27 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 48 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Klor-Con 8 | Potassium Chloride | 45 | 19 |
| Levofloxacin | Levofloxacin | 45 | 36 |
| Propranolol Hcl | Propranolol Hcl | 44 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 24 |
| Estradiol | Estradiol | 43 | suppressed |
| Linzess | Linaclotide | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Temazepam | Temazepam | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 12 |
| Finasteride | Finasteride | 40 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 25 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | suppressed |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 17 |
| Metronidazole | Metronidazole | 35 | 22 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 15 |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 30 | 11 |
| Metolazone | Metolazone | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | 16 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Risperidone | Risperidone | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Colchicine | Colchicine | 19 | 11 |
| Mitigare | Colchicine | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 12 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Famciclovir | Famciclovir | 13 | 11 |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $291.74 · 10 records | Bayer Healthcare Pharmaceuticals Inc. | ELIQUIS, Kerendia, NURTEC ODT, QULIPTA, Saxenda, The Cologuard Plus Collection Kit, UBRELVY, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error